by TractManager | Apr 27, 2017 | Emerging Technology Report
The TrueTear Intranasal Tear Neurostimulator is a nonsurgical, intranasally applied device that consists of a rechargeable handheld stimulator that is used with a disposable 2-pronged hydrogel tip assembly. The prongs are inserted into both nasal passages; the device...
by TractManager | Apr 27, 2017 | Health Technology Assessment
Breast reconstruction (BR) may pose a challenge if the patient’s skin-pectoral muscle pocket cannot adequately support tissue expansion or hold the expander or implant in place. Various options exist for reinforcing coverage of this muscle, including autologous...
by TractManager | Apr 27, 2017 | Health Technology Assessment
Onychomycosis is a fungal infection of the nail. Onychomycosis can cause discomfort, pain, and disfigurement leading to serious physical and occupational limitations. Onychomycosis is a deep-seated, recalcitrant condition with a 40% to 70% recurrence rate, which...
by TractManager | Apr 20, 2017 | Health Technology Assessment
Purpose of Technology: Lidocaine hydrochloride is a local anesthetic with antiarrhythmic properties that may hold utility in the treatment of select patients with intractable neuropathic pain. Intravenous lidocaine helps to suppress spontaneous ectopic discharges of...
by TractManager | Apr 13, 2017 | Emerging Technology Report
Ingrezza is a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of TD. VMAT2 has been identified as a pharmacological target for hyperkinetic movement disorders; Ingrezza causes reversible reduction of dopamine release by selectively inhibiting...
Recent Comments